The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.
The test, which is in development using perspiration as a sample, has shown promising performance in a preliminary study.
Despite the step-up in FDA action against labs offering PGx tests, the success of these programs suggests that access to them isn't being stifled as some feared.
AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.
Comments from Quest suggest lab buys are becoming more complex while others suggest hospitals will remain reluctant to sell so long as premium pricing persists.
The study, sponsored by the US Centers for Disease Control and Prevention, focused on men who have sex with men and members of their social networks.
Recent studies question the clinical utility of tumor mutational burden as a biomarker for immuno-oncology, and the FDA clearance includes no therapeutic indications.
The offering consists of two tranches, $400 million of 2.3 percent senior notes due 2024 and $650 million of 2.95 percent senior notes due 2029.